BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34170566)

  • 1. The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
    Zhang S; Xie Q; Xie S; Chen J; Deng Q; Zhong L; Guo J; Yu Y
    Pharmacotherapy; 2021 Sep; 41(9):781-791. PubMed ID: 34170566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
    Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.
    Lin YJ; Lin SY; Lin CH; Wang ST; Chang SS
    Clin Rheumatol; 2020 May; 39(5):1633-1648. PubMed ID: 31965378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis.
    Zhao L; Cao L; Zhao TY; Yang X; Zhu XX; Zou HJ; Wan WG; Xue Y
    Chin Med J (Engl); 2020 Apr; 133(8):982-993. PubMed ID: 32106120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
    Sapankaew T; Thadanipon K; Ruenroengbun N; Chaiyakittisopon K; Ingsathit A; Numthavaj P; Chaiyakunapruk N; McKay G; Attia J; Thakkinstian A
    BMC Nephrol; 2022 Jun; 23(1):223. PubMed ID: 35739495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
    Barrientos-Regala M; Macabeo RA; Ramirez-Ragasa R; Pestaño NS; Punzalan FER; Tumanan-Mendoza B; Castillo RR
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):461-471. PubMed ID: 32675751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials.
    Sun SS; Zhang DH; Shi Y; Lin CJ; Lin JY
    J Clin Pharm Ther; 2020 Aug; 45(4):729-742. PubMed ID: 32406077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials.
    Xie H; Hu N; Pan T; Wu JC; Yu M; Wang DC
    BMC Pharmacol Toxicol; 2023 Dec; 24(1):79. PubMed ID: 38098046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febuxostat for treating chronic gout.
    Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
    Yu X; Gu M; Zhu Y; Zhang L; Kong W; Zou Y
    Clin Ther; 2022 May; 44(5):723-735.e6. PubMed ID: 35610080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urate-Lowering Drugs and Muscle Injury: A Systematic Review and Network Meta-Analysis.
    Mitsuboshi S; Morizumi M; Kotake K; Kaseda R; Narita I
    J Clin Pharmacol; 2024 Mar; 64(3):288-299. PubMed ID: 37840156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To Treat or Not to Treat? Effect of Urate-Lowering Therapy on Renal Function, Blood Pressure and Safety in Patients with Asymptomatic Hyperuricemia: A Systematic Review and Network Meta-Analysis.
    Tien YY; Shih MC; Tien CP; Huang HK; Tu YK
    J Am Board Fam Med; 2022; 35(1):140-151. PubMed ID: 35039419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials
.
    Song GG; Lee YH
    Int J Clin Pharmacol Ther; 2019 Jul; 57(7):345-352. PubMed ID: 30990408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
    Gupta MK; Singh JA
    Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
    Wang M; Zhang Y; Zhang M; Li H; Wen C; Zhao T; Xie Z; Sun J
    Ann Palliat Med; 2021 Oct; 10(10):10327-10337. PubMed ID: 34498481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.
    Bredemeier M; Lopes LM; Eisenreich MA; Hickmann S; Bongiorno GK; d'Avila R; Morsch ALB; da Silva Stein F; Campos GGD
    BMC Cardiovasc Disord; 2018 Feb; 18(1):24. PubMed ID: 29415653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wu JY; Chang YT; Lin YC; Lee CH; Loh EW; Wu MY; Chang YS; Tam KW
    Pharmacotherapy; 2018 Nov; 38(11):1106-1119. PubMed ID: 30246299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uricosuric medications for chronic gout.
    Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
    Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.